2020
Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects
Kanter J, Smith WR, Desai PC, Treadwell M, Andemariam B, Little J, Nugent D, Claster S, Manwani DG, Baker J, Strouse JJ, Osunkwo I, Stewart RW, King A, Shook LM, Roberts JD, Lanzkron S. Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Advances 2020, 4: 3804-3813. PMID: 32785684, PMCID: PMC7448595, DOI: 10.1182/bloodadvances.2020001743.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnemia, Sickle CellChildHealth Services AccessibilityHematologic DiseasesHumansUnited StatesConceptsSickle cell diseaseSCD centerCell diseaseAdult sickle cell diseaseAcute care utilizationManagement of adultsModel of careSickle cell careHealth care professionalsHealth system levelSCD guidelinesMultisystem illnessSCD careCare utilizationEarly mortalityCenter designationClinical effectivenessClinical centersCare professionalsHematology providersMore cliniciansCare deliveryMost childrenBlood disordersCare
2010
Do African American Men Have Lower Survival From Prostate Cancer Compared With White Men? A Meta-analysis
Sridhar G, Masho SW, Adera T, Ramakrishnan V, Roberts JD. Do African American Men Have Lower Survival From Prostate Cancer Compared With White Men? A Meta-analysis. American Journal Of Men's Health 2010, 4: 189-206. PMID: 20483872, DOI: 10.1177/1557988309353934.Peer-Reviewed Original ResearchConceptsProstate cancer-specific survivalCancer-specific survivalProstate cancerAfrican American menWhite menCancer-related mortalityAmerican menUnadjusted studiesCause mortalityMeta-AnalysisSystematic reviewCancerSurvivalRacial differencesMenSignificant differencesMortalityLower survivalDifferences
2007
Depression and Anxiety in Adults With Sickle Cell Disease: The PiSCES Project
Levenson JL, McClish DK, Dahman BA, Bovbjerg VE, de A. Citero V, Penberthy LT, Aisiku IP, Roberts JD, Roseff SD, Smith WR. Depression and Anxiety in Adults With Sickle Cell Disease: The PiSCES Project. Psychosomatic Medicine 2007, 70: 192-196. PMID: 18158366, DOI: 10.1097/psy.0b013e31815ff5c5.Peer-Reviewed Original ResearchConceptsSickle cell diseaseSCD adultsCell diseaseDepressed subjectsSickle Cell Epidemiology StudyHigher mean painProspective cohort studyHealth-related qualitySF-36 subscalesPrevalence of depressionSickle cell crisisDomains of qualityMean painPain daysPiSCES projectOpioid usageOpioid utilizationCohort studyDaily painPain intensityHealthcare utilizationMore painBaseline variablesCell crisisHemoglobin types
2000
Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.
McLeod HL, Cassidy J, Powrie RH, Priest DG, Zorbas MA, Synold TW, Shibata S, Spicer D, Bissett D, Pithavala YK, Collier MA, Paradiso LJ, Roberts JD. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clinical Cancer Research 2000, 6: 2677-84. PMID: 10914709.Peer-Reviewed Original ResearchConceptsGlycinamide ribonucleotide formyltransferaseCourse 1Systemic clearanceGrade III/IV toxicityGrade II toxicityMin/m2Rapid systemic clearanceVolume of distributionEvaluable patientsSystemic exposurePharmacodynamic evaluationClinical centersBolus injectionPharmacokinetic approachBlood samplesPatient toxicityPatientsElimination patternReproducible ELISAAG2034Course 3Phase IAnticancer agentsPurine synthesis pathwayDe novo purine synthesis pathway